
Canadian growth stories look very different when interest rates are rising and the global bond market is flashing warning signs. Higher borrowing costs make weak balance sheets harder to ignore and increase the focus on companies that already have solid finances and room to grow earnings. This article highlights three stocks from a Canada focused high growth screener that meet both tests and could appeal to long term investors.
The three Canadian growth stories that follow are just a starting sample, since the full screen surfaced 54 more companies with equally compelling narratives that are not covered here.
If you want to identify and analyze candidates that best fit your own risk profile and growth goals, go straight to the Healthy high growth potential screener.
Artemis Gold is squarely tied to the Healthy high growth potential theme because its future hinges on ramping up the Blackwater Gold project. This project is already shifting the business from pure development to cash generating production.
Artemis Gold focuses on identifying and developing gold and silver properties in Canada. Its 100% owned Blackwater Gold project is driving all CA$1.39b of mineral development activity in 2025, and the stock is currently valued at about CA$9.03b.
"Phase 1A is planned to lift processing capacity from 6 million tonnes per year to 8 million tonnes per year, funded from operating cash flow and targeted to have a payback of less than 6 months. This directly targets higher future revenue and operating cash flow once additional throughput is online."
The real swing factor for Artemis Gold now comes from how one big operational decision ripples through future margins and cash generation.
Those margin decisions are exactly what the full narrative for Artemis Gold unpacks, showing how Artemis Gold’s expansion plan could accelerate or stall depending on execution risks and capital discipline.
Hammond Power Solutions designs and manufactures transformers and related power equipment that feed everything from factories to renewables and EV charging projects, generating about CA$1.06b from this line in 2025. The stock is valued at roughly CA$3.54b.
Hammond Power Solutions gives this screener a pure-play way to follow the buildout behind cleaner power and electrification, as its transformer portfolio plugs directly into projects that need more capacity and more reliable grid connections.
"The ramp-up of new manufacturing facilities in Mexico, with expectations to be fully loaded and operational by early next year, will significantly increase production capacity, positioning Hammond to capture greater share of increasing North American demand and support long-term revenue growth while enabling improved operating leverage and margin expansion."
What really matters next is how one pressure on profitability evolves as that extra capacity meets real-world demand and pricing power.
That shifting profit pressure is exactly what the full narrative for Hammond Power Solutions unpacks, showing whether rising capacity masks risks or fuels a sustained acceleration in Hammond Power Solutions.
Theralase Technologies is a clinical stage drug developer working on energy activated small molecules such as Rutherrin and Ruvidar for hard to treat cancers and viral or blood conditions. The company also generates about CA$0.8 million from Cool Laser Therapy devices and carries a market value near CA$54 million.
Theralase Technologies fits the Healthy high growth potential theme through forecasts of 62.63% annual earnings growth and 56.7% revenue growth, off a very small sales base and an unprofitable starting point. That mix of rapid projected expansion and ongoing funding needs leaves plenty riding on how one unseen pressure ultimately resolves.
That hidden pressure is where Theralase Technologies gets interesting, so go straight to the 2 key rewards and 2 important warning signs (1 is major!) and see how the risk reward trade off really lines up.
Fresh ideas move first, and late money often chases prices already flying. Scan curated stock lists while they are still under the radar. If appropriate for your situation, consider acting sooner rather than later.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com